Corcept Therapeutics

Graphic of a line of blocks with percentages on them with one block in yellow showing an arrow increasing
Biotech

Small molecules are 'resurgent' in orphan drug R&D: Evaluate

Small molecules make up almost half of the 20 most valuable orphan drugs in development across biopharma, according to an Evaluate analysis.
James Waldron Mar 12, 2026 10:30am
Magnifying glass amplifying warning sign over falling stock figures

Corcept submitted lead asset for approval despite FDA warning

Jan 30, 2026 2:01pm
On target clinical trial success bullseye score

Corcept racks up ph. 3 cancer win to bounce back from FDA blow

Jan 22, 2026 9:45am
Stop sign

FDA rejects Sanofi MS drug, Corcept Cushing's syndrome therapy

Jan 2, 2026 7:10am
spotlight purple blue light

Corcept unveils promising survival data from phase 2 ALS fail

Jun 5, 2025 8:21am
cancer target detection radiopharma radio

Corcept's phase 3 cancer win sends stock skyrocketing 85%

Mar 31, 2025 10:25am